Korro secures approvals in Australia to commence AATD trial of KRRO-110
Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110,…
All articles by
-
-
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women
Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation and…
-
ImmunityBio and nCartes partner to automate clinical trial data processes
ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials, aiming to transform the…
-
Neuralink receives Health Canada approval to launch trial of implantable device
Neuralink has received approval from Health Canada to launch the first global trial, ‘Canadian Precise Robotically Implanted Brain-Computer Interface’ (CAN-PRIME),…
-
Endeavor doses first subject in Phase IIb trial of ENV-101 for IPF treatment
Endeavor BioMedicines has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial in Australia, assessing the efficacy and…
-
Melt reports topline outcomes from trial of MELT-300 for cataract surgery
Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, non-opioid sedation tablet for…
-
Puma commences Phase II trial of alisertib for breast cancer treatment
Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of aurora kinase A,…
-
Concerto doses first subject in Phase I trial of ENS-002 for atopic dermatitis
Concerto Biosciences has dosed the first subject in a Phase I trial of the three-stain live biotherapeutic product, ENS-002, aimed…
-
GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment
GigaGen, a subsidiary of Grifols, has commenced a Phase I dose escalation trial, with the first patient receiving a dose of…
-
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration,…